Imaging techniques: New avenues in cancer gene and cell therapy

Cancer Gene Therapy

Volumn 24, Issue 1, 2017, Pages 1-5

  Saadatpour, Z ^a   Rezaei, A ^a   Ebrahimnejad, H ^b   Baghaei, B ^c   Bjorklund, G ^d   Chartrand, M ^e   Sahebkar, A ^f   Morovati, H ^g   Mirzaei, H R ^h   Mirzaei, H ^f  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Nutritional and Environmental Medicine   (Norway)

^e DigiCare Behavioral Research   (United States)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; BIOLOGICAL MARKER; TUMOR MARKER;

BIOLOGICAL MONITORING; CANCER GENE THERAPY; CANCER THERAPY; CELL THERAPY; HUMAN; IMAGE ANALYSIS; MALIGNANT NEOPLASM; MOLECULAR IMAGING; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR GENE; ANIMAL; BIOLOGICAL THERAPY; DIAGNOSTIC IMAGING; GENE THERAPY; GENETICS; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BIOMARKERS, TUMOR; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; GENETIC THERAPY; HUMANS; MOLECULAR IMAGING; NEOPLASMS; TREATMENT OUTCOME;

EID: 84994711824     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.61     Document Type: Review

References (73)

1. Fass L. Imaging and cancer: A review. Mol Oncol 2008; 2: 115-152.
2. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008; 8: 94-107.
3. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jafaari MR, Mirzaei HR et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016; 53: 25-32.
4. Gholamin S, Pasdar A, Sadegh Khorrami M, Mirzaei H, Reza Mirzaei H, Salehi R et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: A novel approach to disease diagnosis and treatment. Curr Pharm Des 2016; 22: 397-403.
5. Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for chimeric antigen receptor (CAR) T cells: A potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett 2016; 380: 413-423.
6. Simonian M, Mosallayi M, Mirzaei H Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J Cancer Res Ther 2016.
7. Mirzaei H, Sahebkar A, Yazdi F, Salehi H, Jafari M, Namdar A et al. Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des 2016 (e-pub ahead of print).
8. Salarini R, Sahebkar A, Mirzaei H, Jaafari M, Riahi M, Hadjati J et al. Epi-drugs and Epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets 2015.
9. Mirzaei H, Sahebkar A, Jaafari M, Hadjati J, Javanmard S, Mirzaei H et al. PiggyBac as a novel vector in cancer gene therapy: current perspective. Cancer Gene Ther 2016; 23: 45-47.
10. Mirzaei HR, Sahebkar A, Salehi R, Nahand JS, Karimi E, Jaafari MR et al. Boron neutron capture therapy: moving toward targeted cancer therapy. J Cancer Res Ther 2016; 12: 520-525.
11. Shah K, Jacobs A, Breakefield X, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy 2004; 11: 1175-1187.
12. Sato T, Liu X, Nelson A, Nakanishi M, Kanaji N, Wang X et al. Reduced miR-146a increases prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med 2010; 182: 1020-1029.
13. Räty JK, Liimatainen T, Kaikkonen MU, Gröhn O, Airenne KJ, Ylä-Herttuala S. Non-invasive imaging in gene therapy. Mol Ther 2007; 15: 1579-1586.
14. Sadeghi-Naini A, Falou O, Hudson JM, Bailey C, Burns PN, Yaffe MJ et al. Imaging innovations for cancer therapy response monitoring. Imaging 2012; 4: 311-327.
15. Mirzaei H, Yazdi F, Salehi R, Mirzaei HR. SiRNA and epigenetic aberrations in ovarian cancer. J Cancer Res Ther 2016; 12: 498-508.
16. Mohammadi M, Jaafari M, Mirzaei H, Mirzaei H. Mesenchymal stem cell: A new horizon in cancer gene therapy. Cancer Gene Ther 2016; 23: 285-286.
17. Weissleder R, Mahmood U. Molecular Imaging 1. Radiology 2001; 219: 316-333.
18. Bogdanov A, Weissleder R. The development of in vivo imaging systems to study gene expression. Trends Biotechnol 1998; 16: 5-10.
19. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-580.
20. Blasberg R, Tjuvajev J. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med Mol Imag 1999; 43: 163.
21. Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H et al. Application of mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents. Curr Med Chem 2016; 23: 455-463.
22. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
23. Akbar S, Fazle M, Abe M, Yoshida O, Murakami H, Onji M. Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes. Curr Med Chem 2006; 13: 3113-3119.
24. Dudley ME, Rosenberg SA. Adoptive-cell-Transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
25. Gilkeson RC, Sachs PB. Dual energy subtraction digital radiography: Technical considerations, clinical applications, and imaging pitfalls. J Thorac Imag 2006; 21: 303-313.
26. Campadelli P, Casiraghi E, Artioli D. A fully automated method for lung nodule detection from postero-Anterior chest radiographs. IEEE Trans Med Imag 2006; 25: 1588-1603.
27. Simon CJ, Dupuy DE (eds). Percutaneous Minimally Invasive Therapies in the Treatment of Bone Tumors: Thermal Ablation. Thieme Medical Publishers: New York, NY, USA, 2006.
28. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher C. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2008; 98: 289-293.
29. Liapi E, Geschwind J-F, Vossen JA, Buijs M, Georgiades CS, Bluemke DA et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. Am J Roentgenol 2008; 190: 67-73.
30. Plewes DB, Bishop J, Samani A, Sciarretta J. Visualization and quantification of breast cancer biomechanical properties with magnetic resonance elastography. Phys Med Biol 2000; 45: 1591.
31. Helbich TH, Roberts TP, Gossmann A, Wendland MF, Shames DM, Adachi M et al. Quantitative gadopentetate enhanced MRI of breast tumors: Testing of different analytic methods. Magnet Reson Med 2000; 44: 915-924.
32. Bartella L, Huang W. Proton (1H) MR spectroscopy of the breast 1. Radiographics 2007; 27(Suppl 1 ): S241-S252.
33. Kopelman D, Inbar Y, Hanannel A, Dank G, Freundlich D, Perel A et al. Magnetic resonance guided focused ultrasound surgery (MRgFUS). Four ablation treatments of a single canine hepatocellular adenoma. HPB 2006; 8: 292-298.
34. Vogl TJ, Mayer HP, Zangos S, Selby JB Jr, Ackermann H, Mayer FB. Prostate cancer: MR imaging-guided galvanotherapy-Technical development and first clinical results 1. Radiology 2007; 245: 895-902.
35. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC, Leidich R et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205-212.
36. Fahey B, Nelson R, Bradway D, Hsu S, Dumont D, Trahey G. In vivo visualization of abdominal malignancies with acoustic radiation force elastography. Phys Med Biol 2007; 53: 279.
37. Paliwal S, Sundaram J, Mitragotri S. Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer 2005; 92: 499-502.
38. Pogue BW, Poplack SP, McBride TO, Wells WA, Osterman KS, Osterberg UL et al. Quantitative hemoglobin tomography with diffuse near-infrared spectroscopy: pilot results in the breast 1. Radiology 2001; 218: 261-266.
39. Kao T-J, Saulnier GJ, Xia H, Tamma C, Newell J, Isaacson D. A compensated radiolucent electrode array for combined EIT and mammography. Physiol Measure 2007; 28: S291.
40. Ntziachristos V, Yodh A, Schnall MD, Chance B. MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia 2002; 4: 347-354.
41. Hung S-C, Deng W-P, Yang WK, Liu R-S, Lee C-C, Su T-C et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11: 7749-7756.
42. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006; 47: 1241-1248.
43. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292.
44. Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS et al. Assessment of proliferation in vivo using 2-[11C] thymidine positron emission tomography in advanced intra-Abdominal malignancies. Cancer Res 2002; 62: 5698-5702.
45. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM et al. 11C-Acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549-555.
46. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102: 5524-5529.
47. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004; 22: 3593-3607.
48. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 2006; 60: 353-366.
49. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L et al. Non-invasive assessment of vector-mediated gene expression in a phase I/II clinical glioma gene therapy trial by positron emission tomography. Lancet 2001; 358: 727-729.
50. la Fougère C, Suchorska B, Bartenstein P, Kreth F-W, Tonn J-C. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011; 13: 806-819.
51. Verwijnen SM, Sillevis Smith PA, Hoeben RC, Rabelink MJ, Wiebe L, Curiel DT et al. Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-Thymidine kinase gene and the somatostatin receptor subtype 2 gene. Cancer Biother Radiopharmaceut 2004; 19: 111-120.
52. Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martí-Climent J, Ruiz M et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005; 128: 1787-1795.
53. Alauddin MM, Shahinian A, Gordon EM, Conti PS. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-Tk expression in a human breast cancer model. Mol Imaging 2004; 3: 76-84.
54. Zinn K, Chaudhuri T, Buchsbaum D, Mountz J, Rogers B. Detection and measurement of in vitro gene transfer by gamma camera imaging. Gene Ther 2001; 8: 291-299.
55. Simonova M, Wall A, Weissleder R, Bogdanov A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res 2000; 60: 6656-6662.
56. Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R. Human transferrin receptor gene as a marker gene for MR imaging 1. Radiology 2001; 221: 244-250.
57. Ichikawa T, Högemann D, Saeki Y, Tyminski E, Terada K, Weissleder R et al. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002; 4: 523-530.
58. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 2005; 7: 109-117.
59. Poptani H, Puumalainen A-M, Gröhn O, Loimas S, Kainulainen R, Ylä-Herttuala S et al. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1997; 5: 101-109.
60. Chaudhuri TR, Rogers BE, Buchsbaum DJ, Mountz JM, Zinn KR. A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol 2001; 83: 432-438.
61. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1a hypoxia response element VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000; 60: 6248-6252.
62. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H et al. Anti-Tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008; 57: 1279-1289.
63. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A et al. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-Antigen. Int Immunol 2009; 21: 155-165.
64. Agger R, Petersen MS, Petersen CC, Hansen SB, Stødkilde-Jørgensen H, Skands U et al. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. J Immunother 2007; 30: 29-39.
65. Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S et al. Monitoring the efficacy of adoptively transferred prostate cancer-Targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med 2008; 49: 1162-1170.
66. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol 2004; 31: 1021-1031.
67. Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother 2007; 56: 155-163.
68. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003; 63: 6838-6846.
69. Tavri S, Jha P, Meier R, Henning TD, Möller T, Hostetter D et al. Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging 2009; 8: 15-26.
70. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor bearing mice by bioluminescence imaging. Stem Cells 2009; 27: 1548-1558.
71. Vuu K, Xie J, McDonald MA, Bernardo M, Hunter F, Zhang Y et al. Gadoliniumrhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug Chem 2005; 16: 995-999.
72. Rad AM, Iskander A, Janic B, Knight RA, Arbab AS, Soltanian-Zadeh H. AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: A preliminary study. BMC Biotechnol 2009; 9: 28.
73. Takashima K, Fujiwara H, Inada S, Atsuji K, Araki Y, Kubota T et al. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases. Anticancer Res 2006; 26: 3327-3332.